logo-loader
viewHumanigen, Inc.

Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article

The study preventing GM-CSF signaling reduces acute GvHD, which is what Humanigen's drug, lenzilumab is designed to do

Person in scrubs reading tablet
The company is currently planning a Phase 2 trial in the UK in patients at high risk of acute GvHD

Humanigen Inc (OTCMKTS:HGEN) told investors Tuesday that a recent study published in the medical journal Blood Advances supports its strategy in the development of a treatment for severe graft-versus-host disease (GvHD). 

The study found that GM-CSF, a protein involved in the creation of white blood cells, is necessary to initiate a cascade that drives lethal GvHD. If GM-CSF isn’t able to give off signals, however, the study showed a significant reduction in the disease.

That’s where Humanigen’s drug lenzilumab, an anti-GM-CSF immunotherapy, comes in.

READ: Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

The California-based company is currently planning a Phase 2 trial in the UK for patients at high risk of acute GvHD. 

In July, Humanigen received an exclusive worldwide license from the University of Zurich for technologies to prevent and treat GvHD through GM-CSF neutralization.

Blood Advances is the official journal of the American Society of Hematology. The article, published Tuesday, is entitled “Donor T-cell derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.”

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: 0.43 USD

OTCQB:HGEN
Market: OTCQB
Market Cap: $48.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen updates on its clinical collaboration with Gilead Sciences...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco.  Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with...

on 10/23/2019

2 min read